Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMRNASDAQ:NLTXNASDAQ:OGINASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$2.59-5.5%$2.30$1.61▼$11.20$175.44M0.79819,620 shs1.52 million shsNLTXNeoleukin Therapeutics$18.30-0.7%$16.65$2.03▼$14.36$171.98M1.1150,104 shs203,614 shsOGIOrganigram Global$1.29-2.3%$1.24$0.85▼$2.08$176.80M1.37658,469 shs673,485 shsSTTKShattuck Labs$0.96-1.8%$0.98$0.69▼$4.99$46.67M1.72346,502 shs108,548 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics-5.47%-10.07%+34.20%+1.97%-67.09%NLTXNeoleukin Therapeutics0.00%-10.29%-1.35%+28.78%-39.64%OGIOrganigram Global-2.27%-7.86%-3.73%+16.22%-16.23%STTKShattuck Labs-1.80%-5.26%-10.57%-20.26%-79.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLRMRLarimar Therapeutics2.9545 of 5 stars3.63.00.00.03.31.70.6NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global1.1227 of 5 stars0.01.00.00.03.20.02.5STTKShattuck Labs2.1359 of 5 stars3.42.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.11Buy$19.67659.33% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/ASTTKShattuck Labs 2.83Moderate Buy$7.50683.78% UpsideCurrent Analyst Ratings BreakdownLatest STTK, OGI, NLTX, and LRMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025STTKShattuck LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/27/2025STTKShattuck LabsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AOGIOrganigram Global$117.47M1.47N/AN/A$2.07 per share0.62STTKShattuck Labs$5.72M8.01N/AN/A$1.67 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AOGIOrganigram Global-$33.39M$0.1012.90N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)STTKShattuck Labs-$75.41M-$1.39N/AN/AN/A-1,156.46%-79.69%-69.13%7/30/2025 (Estimated)Latest STTK, OGI, NLTX, and LRMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025STTKShattuck Labs-$0.29-$0.27+$0.02-$0.27N/AN/A4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/27/2025Q4 2024STTKShattuck Labs-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A7.487.48NLTXNeoleukin TherapeuticsN/A15.3315.33OGIOrganigram GlobalN/A3.421.90STTKShattuck LabsN/A9.089.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%NLTXNeoleukin Therapeutics52.37%OGIOrganigram Global34.63%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%NLTXNeoleukin Therapeutics1.58%OGIOrganigram Global0.09%STTKShattuck Labs12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataOGIOrganigram Global860133.94 million133.82 millionOptionableSTTKShattuck Labs10047.90 million42.15 millionOptionableSTTK, OGI, NLTX, and LRMR HeadlinesRecent News About These CompaniesHere's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn SituationJune 13, 2025 | finance.yahoo.comShattuck Labs Advances SL-325 Program Amid Financial ProgressMay 6, 2025 | tipranks.comShattuck Labs Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 1, 2025 | globenewswire.comShattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comShattuck Labs Full Year 2024 Earnings: Misses ExpectationsMarch 29, 2025 | uk.finance.yahoo.comShattuck Labs reports Q4 EPS (37c), consensus (32c)March 29, 2025 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Shattuck Labs (STTK)March 29, 2025 | markets.businessinsider.comShattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | finanznachrichten.deShattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business HighlightsMarch 27, 2025 | globenewswire.comLeerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform RecommendationMarch 18, 2025 | msn.comShattuck Labs initiated with an Outperform at LeerinkMarch 17, 2025 | markets.businessinsider.comFavourable Signals For Shattuck Labs: Numerous Insiders Acquired StockMarch 11, 2025 | finance.yahoo.comH.C. Wainwright Keeps Their Hold Rating on Shattuck Labs (STTK)February 21, 2025 | markets.businessinsider.comShattuck Labs’ SL-325 shows positive results in inflammatory bowel diseaseFebruary 20, 2025 | markets.businessinsider.comShattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 20, 2025 | globenewswire.comShattuck Labs to Present Pre-Clinical Data on SL-325 at ECCO 2025 Conference in BerlinFebruary 13, 2025 | quiverquant.comShattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025February 13, 2025 | globenewswire.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | markets.businessinsider.comShattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis CongressFebruary 4, 2025 | quiverquant.comShattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis CongressFebruary 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPE3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketSTTK, OGI, NLTX, and LRMR Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$2.59 -0.15 (-5.47%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.37 -0.22 (-8.34%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Neoleukin Therapeutics NASDAQ:NLTX$18.30 -0.12 (-0.65%) As of 06/18/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Organigram Global NASDAQ:OGI$1.29 -0.03 (-2.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.34 +0.05 (+3.88%) As of 06/20/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Shattuck Labs NASDAQ:STTK$0.96 -0.02 (-1.80%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.95 -0.01 (-0.93%) As of 06/20/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
